Title : Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug-Drug Interactions and Pediatric Dose Regimens.

Pub. Date : 2021 Nov

PMID : 34196005






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Selumetinib (ARRY-142886), an oral, potent and highly selective allosteric MEK1/2 inhibitor, is approved by the US FDA for the treatment of pediatric patients aged 2 years and older with neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas. AZD 6244 neurofibromin 1 Homo sapiens
2 Selumetinib (ARRY-142886), an oral, potent and highly selective allosteric MEK1/2 inhibitor, is approved by the US FDA for the treatment of pediatric patients aged 2 years and older with neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas. AZD 6244 neurofibromin 1 Homo sapiens